Clinical Trial

Evaluation of XYA02 in Patients With Advanced Solid Tumors

Name: Evaluation of XYA02 in Patients With Advanced Solid Tumors — clinical trial record (NCT07670312)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-06-25.

Trial Details

NCT Number	NCT07670312
Lead Sponsor	XYone Therapeutics, Inc Collaborators: Novotech (Australia) Pty Limited
Conditions	MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma, Colorectal Cancer, Pancreatic Adenocarcinoma
Enrollment	190 participants
Start Date	2026-07-15
Primary Completion	2029-07-15 (estimated)
Study Completion	2030-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-13